FIMECS
Latest round
- Series B
Last raised
- Jan 2022
Total raised
- $15M
Investors
- 4
About FIMECS
D., FIMECS, Inc. operates as a provider of targeted protein degradation drug discovery solutions to global pharmaceutical companies focusing on immuno-oncology and oncology research. In February 2024, RaQualia Pharma Inc.5 billion. The company provides a wide range of drug discovery solutions using proprietary E3 ligase binders and the RaPPIDS platform for the degradation of disease-relevant proteins.
Who invested in FIMECS
4 investors across 2 rounds
See all investors in FIMECS
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about FIMECS
Who invested in FIMECS?
FIMECS has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has FIMECS raised?
FIMECS has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did FIMECS last raise money?
FIMECS's most recent round on record is a Series B, in Jan 2022.
What does FIMECS do?
FIMECS is a biotechnology company.
Where is FIMECS headquartered?
FIMECS is headquartered in Fujisawa-shi, Japan.
Which VCs invest in companies like FIMECS?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at FIMECS's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like FIMECS? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.